| Literature DB >> 29135992 |
Valentin Scherz1, Christian Durussel1, Gilbert Greub1.
Abstract
Given the importance of microbiology results on patient care, high quality standards are expected. Internal quality assurance (IQA) could mitigate the limitations of internal quality control, competency assessment and external quality assurance, adding a longitudinal insight, including pre- and post-analytical steps. Here, we implemented an IQA program in our clinical microbiology facilities with blind resubmission of routine samples during 22 months. One-hundred-and-twenty-one out of 123 (98.4%) serological analyses and 112 out of 122 (91.8%) molecular analyses were concordant. Among the discordances in molecular biology analyses, 6 results were low positive samples that turned out negative, likely due to stochastic repartition of nucleic acids. Moreover, one identified retranscription error led us to implement automated results transmission from the Applied Biosystems instruments to the laboratory information system (LIS). Regarding Gram stain microscopy, 560 out of 745 (75.2%) of compared parameters were concordant. As many as 67 out of 84 (79.8%) pairs of culture results were similar, including 16 sterile pairs, 27 having identical identification or description and semi-quantification and 24 only showing variations in semi-quantification with identical description or identification of colonies. Seventeen pairs had diverging identification or description of colonies. Culture was twice only done for one member of the pairs. Regarding antibiotic susceptibility testing, a major discrepancy was observed in 5 out of 48 results (10.4%). In conclusion, serological tests were highly reproducible. Molecular diagnosis also revealed to be robust except when the amounts of nucleic acids present in the sample were close to the limits of detection. Conventional microbiology was less robust with major discrepancies reaching 39.5% of the samples for microscopy. Similarly, culture and antibiotic susceptibility testing were prone to discrepancies. This work was ground for reconsidering multiples aspects of our practices and demonstrates the importance of IQA to complete the other quality management procedures.Entities:
Mesh:
Year: 2017 PMID: 29135992 PMCID: PMC5685576 DOI: 10.1371/journal.pone.0187263
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Overview of results agreements in our different laboratories.
| Percentage of agreement | Discordant analyses | Clinically significant discordances | Time between replicates | |
|---|---|---|---|---|
| Mean (SD) | ||||
| p25/p50/p75 (in hours) | ||||
| 98.4% | 2/123 | 1/2 | 28 (19.1) | |
| 19.1/24.6/41.6 | ||||
| 91.8% | 10/122 | 6/10 | ||
| Qualitative results | 95.1% | 6/122 | 6/6 | 182.8 (45.8) |
| Quantitative results | 82.6% | 4/23 | 0/4 | 169.1/191.5/215.8 |
| 75.2% | 185/745 | 13/71 | 10.3 (9.5) | |
| 50.0% | 43/86 | 13/43 | ||
| Aggregated by panels | 75.0% | 12/48 | 1/12 | 5.0/6.5/8.2 |
| Single antibiotics | 96.4% | 25/759 | 1/25 |
This table shows an overview of the agreement, discordance and clinical significance of discordances for the three laboratories. The column “Time between replicates” indicates the distribution of time, in hours, between the management of the original sample and its replicate. For AST, results were analyzed once to see whether the panels done for the same bacteria had identical results (Aggregated by panels) and once to see whether every single antibiotic tested had the same results twice (Single antibiotics).
*1 overall agreement for all parameters;
*2 results aggregated per samples;
SD = standard deviation; p25 = percentile 25; p50 = percentile 50, p75 = percentile 75.
Fig 1Molecular biology results pairs reparation.
Straight line represents the line of identity, expressing perfect match. Pointed lines delaminate a ± 3.3 Ct tolerance margin. Represented are low positive versus negative results (n = 5, diamonds); moderate positive versus negative results (n = 1, square), quantitative discrepancies with over one log10 difference in copies/ml (straight triangles, n = 3), quantitative discrepancy with difference over 3.3Ct but less than one log10 (reversed triangle, n = 1); agreeing positive results (rounds, n = 20). 92 negative agreeing results are not represented on this figure. Note that these results here include two negative pairs and one positive pair of tests that were not quantitatively reported in copies/ml but only reported in Ct number by the laboratory.
Repartition of Gram staining discrepancies.
| Identical result | Negligible discrepancy | Minor discrepancy | Major discrepancy | Total | Rate of double negativity | Weighted Kappa | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 37 | 29 | 8 | 7 | 81 | 0.49 | ||||||
| 51 | 9 | 5 | 16 | 81 | 0.55 | ||||||
| 58 | 11 | 6 | 6 | 81 | 0.62 | ||||||
| 49 | 21 | 4 | 7 | 81 | 0.66 | ||||||
| 57 | 0 | 0 | 0 | 57 | N.R. | ||||||
| 60 | 3 | 0 | 1 | 64 | 0.69 | ||||||
| 48 | 18 | 11 | 4 | 81 | 0.63 | ||||||
| 53 | 1 | 0 | 3 | 57 | N.R. | ||||||
| 69 | 8 | 1 | 3 | 81 | 0.79 | ||||||
| 78 | 2 | 0 | 1 | 81 | N.R. | ||||||
| 560 | 102 | 35 | 48 | 745 | |||||||
Gram staining of routine samples and IQA samples were compared and discrepancy amplitudes were categorized according to S1B Table for each parameter. Rate of double negativity represents the proportion of results that were negative for both the routine and IQA sample. Weighted Kappa score express the level of concordance between two rates, not only due to natural probability of agreement. Score of -1 expresses perfect disagreement; 0 expresses agreement corresponding to random; probability; 1 expresses perfect agreement. [36,37]
GP = Gram-positive; GN = Gram-negative; NR = non-relevant
Culture results: Agreement and description of discrepant cases.
| Unnecessary cultivation of vaginal swab for the IQA sample, with otherwise agreeing microscopy results showing no potential pathogen. Difference of procedure considered as of negligible impact. | |
| Respiratory sample was not cultivated for patient’s sample because of microscopy results suggestive of a contamination, whereas the IQA microcopy results led to cultivation and growth of moderate quantities of | |
| Low quantities of | |
| Low quantities of | |
| Low quantities of | |
| Two strains of | |
| Similar growth on plates but different interpretation with only a description of the grown colonies for the patient’s respiratory sample (low quantities of | |
| Similar growth but different interpretation with only a partial identification for the patient’s respiratory sample (low quantifies of | |
| Similar growth but different interpretation with only description for IQA respiratory sample (low quantities of Gram-negative | |
| Low quantities of | |
| Low quantities of | |
| Moderate quantities of | |
| Low quantities of | |
| Low quantities of | |
| Low quantities of | |
| High quantities of | |
* indicates the colonies that led to an AST when present.
Comparison of AST panels accomplished for the same identified bacterial species.
| Identical AST results | 36 | |
| AST including at least one minor discrepancy | 7 | |
| AST including at least one major discrepancy | 5 | |
Major and minor categories as defined in S1C Table.
AST panels without panels for the same bacteria in the results of the corresponding sample.
Fig 2AST agreement, per antibiotics.
Counts of concordant pairs of AST results are in green, minor discrepancies (sensitive versus intermediate or intermediate versus resistant) are in yellow and major discrepancies (sensitive versus resistant) are in red. Only antibiotics tested more than 10 times are represented. Complete results are available in S2 Table. AMC = amoxicillin-clavulanic acid; AMK = amikacin; AMP = ampicillin; AMX = amoxicillin; CAZ = ceftazidime; CIP = ciprofloxacin; CLI = clindamycin; CLR = clarithromycin; CRO = ceftriaxone; CXM = cefuroxime; ERY = erythromycin; ETP = ertapenem; FEP = cefepime; FOF = fosfomycin; GEN = gentamicin; IPM = imipenem; LVX = levofloxacin; MEM = meropenem; NIT = nitrofurantoin; PEN = penicillin; SXT = trimethoprim-sulfamethoxazole; TEC = teicoplanin; TET = tetracycline; TOB = tobramycin; TZP = piperacillin-tazobactam; VAN = vancomycin.